Skip to main content

Advertisement

SpringerLink
Log in

Lipid Parameters, Doses and Blood Levels of Calcineurin Inhibitors in Renal Transplant Patients

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

The calcineurin inhibitors (CNIs) [cyclosporin A (CsA) and tacrolimus (Tac)] are currently the most widely prescribed drugs for maintenance of immunosuppression after renal transplantation. These immunosuppressants are associated with side effects such as hyperlipidemia. We evaluated the differential effects of different CNIs on serum lipid parameters in renal transplant patients. Moreover, the aim of this study is to investigate the relationships between doses and blood levels of CNIs, and blood levels of CNIs and lipid parameters retrospectively. Two groups of 98 non-diabetic renal transplant patients, each treated with different CNIs, were studied: group A (n = 50, mean age: 31 ± 10 years), CsA, mycophenolate mofetil/azathioprin, steroid; group B (I = 48, mean age: 34 ± 12 years), Tac, mycophenolate mofetil/azathioprin, steroid. In renal transplant patients, CNIs blood levels and doses were examined at 1, 3, 6, 9, and 12 months after transplantation. Biochemical laboratory parameters including plasma lipids [total-cholesterol (CHOL), low-density lipoprotein (LDL)–CHOL, high-density lipoprotein (HDL)–CHOL, and triglycerides (TG)], CNI levels and doses were examined at 1, 3, 6, 9, and 12 months after transplantation. None of the patients received anti-lipidemic drugs during the study period. Blood levels of CNIs were detectable in all whole-blood samples by Cloned- Enzyme-Donor Immunoassay (CEDIA). The relationship between CNIs blood levels and CHOL, (LDL)–CHOL, HDL–CHOL, TG were evaluated. The mean serum CHOL levels and LDL–CHOL levels of patients in group A were found significantly higher than the patients in group B during the 12 month of follow up (p < 0.05). There was no significant difference in TG and HDL–CHOL plasma levels between group A and group B (p > 0.005). In group A the daily dose of CsA was significantly correlated with the mean blood levels of CsA at the 1st and 3rd months (r = 0.387, p = 0.005; r = 0.386, p = 0.006), respectively. In group A, the daily dose of CsA was significantly correlated with the mean serum TG levels during the 12 month of follow up (r = 0.420, p = 0.003). In group B, the daily dose of Tac was significantly correlated with the mean blood level of Tac (r = 0.335, p = 0.020) at the 1st month. No correlation was found between mean Tac blood levels and lipid parameters during the 12-month of follow up (p > 0.05). Significant positive correlation was observed between the CsA blood levels and LDL–CHOL levels (r = 0.338, p = 0.027) at the 3rd month. In the renal transplant patients with well functioning grafts, CsA therapy is associated with increased CHOL and LDL–CHOL ratio which represents an increased atherogenic risk tended to be associated with CsA. Serum LDL–CHOL levels may be effected by blood CsA levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Thomson W, Starzl TE Immunosuppressive drugs: developments in anti-rejection. London: Edward Arnold; 1994. p. 235.

  2. Thomson W. FK 506-How much potential? Immunol Today. 1989;10:6–10.

    Article  PubMed  CAS  Google Scholar 

  3. Calne RY. Immunosuppression in liver transplantation. N Engl J Med. 1994;331:1154–5.

    Article  PubMed  CAS  Google Scholar 

  4. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc. 2004;36(2):25–32.

    Article  Google Scholar 

  5. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, et al. Discovery of FK 506, a novel immunosuppressant isolated from Streptomyces tsukabaensis. Transplant Proc. 1987;6(91):4–8.

    Google Scholar 

  6. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK 506, a novel immunosuppressant isolated from a Streptomyces:I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987;40:1249–55.

    Article  CAS  Google Scholar 

  7. Wanner C, Quaschning T. Abnormal lipid metabolism after renal transplantation. Ann Transplant. 2001;6(1):5–8.

    PubMed  CAS  Google Scholar 

  8. Ligtenberg G, Hene RJ, Blankestıjn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol. 2001;12:368–73.

    PubMed  CAS  Google Scholar 

  9. Nemati E, Einollahi B, Taheri S, Moghani LM, Kalantar E, Simforoosh N, et al. Cyclosporine trough (C0) and 2-hour postdose (C2) levels: which one is a predictor of graft loss? Transplant Proc. 2007;39(4):1223–4.

    Article  PubMed  CAS  Google Scholar 

  10. Badiou S, Cristol JP, Mourad G. Dyslipidemia following kidney transplantation: diagnosis and treatment. Curr Diab Rep. 2009;9:305–11.

    Article  PubMed  CAS  Google Scholar 

  11. Quaschning T, Mainka T, Nauck M, Christian LR, Wanner C, Kramer-Guth A. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int. 1999;56(71):235–7.

    Article  Google Scholar 

  12. Colak T, Karakayali, Yagmurdur MC, Moray G. Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients. Transplant Proc. 2002;34:2081–2.

    Article  PubMed  CAS  Google Scholar 

  13. Kuster GH, Bartucci MR, Mayes JT, Schulac JA. The effects of cyclosporine and prednisone on serum lipid and (apo) lipoprotein levels in renal transplant recipients. J Am Soc Nephrol. 1995;5:2077.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Biology Department, Istanbul Medicine Faculty, Istanbul University, Capa, Fatih, Istanbul, Turkey

    Hayriye Senturk Ciftci & Mehmet Gurtekin

  2. Medical Biology Department, Medicine Faculty, Katip Celebi University, Cigli, Izmir, Turkey

    Tulay Kilicaslan Ayna

  3. Nephrology Department, Istanbul Medicine Faculty, Istanbul University, Capa, Fatih, Istanbul, Turkey

    Yasar Kerem Calıskan & Aydin Turkmen

Authors
  1. Hayriye Senturk Ciftci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tulay Kilicaslan Ayna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasar Kerem Calıskan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aydin Turkmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mehmet Gurtekin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hayriye Senturk Ciftci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ciftci, H.S., Ayna, T.K., Calıskan, Y.K. et al. Lipid Parameters, Doses and Blood Levels of Calcineurin Inhibitors in Renal Transplant Patients. Ind J Clin Biochem 28, 164–168 (2013). https://doi.org/10.1007/s12291-012-0251-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-012-0251-6

Keywords

Search

Navigation